Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 June 2019Website:
http://www.stoketherapeutics.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 74 min agoDividend
Analysts recommendations
Institutional Ownership
STOK Latest News
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.55 per share a year ago.
STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026.
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.69 per share a year ago.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 4:00 p.m. ET TD Cowen Genetic Medicines & RNA Summit Date: Thursday, June 20, 2024 Time: 1.
Stoke Therapeutics, Inc. (STOK) reported a quarterly loss of $0.57 per share, slightly better than the expected loss of $0.60 per share according to the Zacks Consensus Estimate. This is compared to a loss of $0.53 per share in the same quarter last year.
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What type of business is Stoke Therapeutics?
Stoke Therapeutics, Inc., a early-stage biopharmaceutical company, is developing new antisense oligonucleotide drugs for the treatment of underlying causes of severe genetic diseases. Its lead drug candidate, STK-001, is being used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to conduct genetic testing. Previously known as ASOthera Pharmaceuticals, Inc., the company changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
What sector is Stoke Therapeutics in?
Stoke Therapeutics is in the Healthcare sector
What industry is Stoke Therapeutics in?
Stoke Therapeutics is in the Biotechnology industry
What country is Stoke Therapeutics from?
Stoke Therapeutics is headquartered in United States
When did Stoke Therapeutics go public?
Stoke Therapeutics initial public offering (IPO) was on 19 June 2019
What is Stoke Therapeutics website?
https://www.stoketherapeutics.com
Is Stoke Therapeutics in the S&P 500?
No, Stoke Therapeutics is not included in the S&P 500 index
Is Stoke Therapeutics in the NASDAQ 100?
No, Stoke Therapeutics is not included in the NASDAQ 100 index
Is Stoke Therapeutics in the Dow Jones?
No, Stoke Therapeutics is not included in the Dow Jones index
When was Stoke Therapeutics the previous earnings report?
No data
When does Stoke Therapeutics earnings report?
The next expected earnings date for Stoke Therapeutics is 07 November 2024